- $83.95bn
- $102.18bn
- £31.38bn
- 70
- 69
- 84
- 87
REG - GlaxoSmithKline PLC - SK bio & GSK start Ph3 Covid-19 vaccine trial
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - Law Debenture Corp - Net Asset Value(s)
AnnouncementREG - Ruffer Investment Co - Investment Manager’s Year End Review
AnnouncementREG - Law Debenture Corp - Net Asset Value(s)
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Block Listing Application
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - 2nd Quarter Results
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Board Committee Changes
AnnouncementREG - GlaxoSmithKline PLC - CEO Designate of new Consumer Healthcare company
AnnouncementREG - GlaxoSmithKline PLC - GSK announces daprodustat phase 3 headline results
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement